Total Payments
$132,511
2024 Payments
$4,528
Companies
75
Transactions
650
Medicare Patients
12,715
Medicare Billing
$7.7M
Payment Breakdown by Category
Consulting$57,692 (43.5%)
Other$48,400 (36.5%)
Food & Beverage$13,889 (10.5%)
Travel$12,081 (9.1%)
Education$447.79 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $57,692 | 31 | 43.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $46,150 | 24 | 34.8% |
| Food and Beverage | $13,889 | 515 | 10.5% |
| Travel and Lodging | $12,081 | 59 | 9.1% |
| Honoraria | $2,250 | 1 | 1.7% |
| Education | $447.79 | 20 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| TESARO, Inc. | $45,043 | 75 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $17,689 | 38 | $0 (2024) |
| Bayer HealthCare Pharmaceuticals Inc. | $12,697 | 45 | $0 (2022) |
| GlaxoSmithKline, LLC. | $11,369 | 20 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $7,621 | 42 | $0 (2024) |
| Kite Pharma, Inc. | $7,583 | 25 | $0 (2024) |
| Genentech, Inc. | $5,031 | 5 | $0 (2023) |
| Celgene Corporation | $4,757 | 34 | $0 (2024) |
| Exelixis Inc. | $2,952 | 15 | $0 (2024) |
| ABBVIE INC. | $2,470 | 10 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,528 | 58 | Kite Pharma, Inc. ($2,080) |
| 2023 | $13,654 | 130 | Genentech, Inc. ($5,011) |
| 2022 | $22,139 | 61 | GlaxoSmithKline, LLC. ($7,935) |
| 2021 | $8,424 | 52 | AstraZeneca Pharmaceuticals LP ($4,487) |
| 2020 | $10,004 | 54 | Celgene Corporation ($3,129) |
| 2019 | $28,339 | 113 | TESARO, Inc. ($15,273) |
| 2018 | $14,303 | 83 | TESARO, Inc. ($7,696) |
| 2017 | $31,120 | 99 | TESARO, Inc. ($22,074) |
All Payment Transactions
650 individual payment records from CMS Open Payments — Page 1 of 26
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $26.50 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 12/17/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | In-kind items and services | $23.58 | General |
| Category: Oncology | ||||||
| 12/16/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $26.52 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/12/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $18.91 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $130.11 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $100.87 | General |
| 12/05/2024 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $26.81 | General |
| Category: Hematology | ||||||
| 12/04/2024 | Janssen Biotech, Inc. | CARVYKTI (Drug) | Food and Beverage | In-kind items and services | $15.57 | General |
| Category: Oncology | ||||||
| 11/21/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $20.52 | General |
| Category: Oncology | ||||||
| 11/19/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $27.89 | General |
| Category: Oncology | ||||||
| 11/18/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $21.11 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $28.97 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ICLUSIG (Drug) | Food and Beverage | In-kind items and services | $28.82 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $20.11 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $442.50 | General |
| 10/28/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $33.27 | General |
| Category: Oncology | ||||||
| 10/25/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $18.36 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $21.80 | General |
| Category: Oncology | ||||||
| 10/23/2024 | Immunocore Limited | KIMMTRAK (Drug) | Food and Beverage | In-kind items and services | $32.30 | General |
| Category: Oncology | ||||||
| 10/22/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $27.14 | General |
| Category: Oncology | ||||||
| 10/14/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG | Food and Beverage | In-kind items and services | $25.50 | General |
| Category: ONCOLOGY | ||||||
| 09/25/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA, BALVERSA | Food and Beverage | In-kind items and services | $21.96 | General |
| Category: Oncology | ||||||
| 09/20/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $21.64 | General |
| Category: DESMOID TUMORS | ||||||
| 09/18/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $20.83 | General |
| Category: Oncology | ||||||
| 09/09/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Education | In-kind items and services | $64.50 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 47 | 2,823 | 104,768 | $7.8M | $2.2M |
| 2022 | 50 | 2,872 | 109,155 | $7.0M | $2.0M |
| 2021 | 64 | 3,646 | 132,902 | $6.4M | $2.3M |
| 2020 | 57 | 3,374 | 98,929 | $3.3M | $1.2M |
Total Patients
12,715
Total Services
445,754
Medicare Billing
$7.7M
Procedure Codes
218
All Medicare Procedures & Services
218 procedure records from CMS Medicare Utilization — Page 1 of 9
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 22 | 33,000 | $4.2M | $1.4M | 34.3% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 66 | 9,421 | $513,445 | $174,620 | 34.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 557 | 1,315 | $401,075 | $146,368 | 36.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 175 | 582 | $236,292 | $93,627 | 39.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 80 | 501 | $257,514 | $69,356 | 26.9% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 18 | 822 | $882,828 | $66,314 | 7.5% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 41 | 7,720 | $349,330 | $45,313 | 13.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 84 | 249 | $55,278 | $17,750 | 32.1% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 13 | 16,330 | $61,238 | $14,441 | 23.6% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 34 | 209 | $52,459 | $13,862 | 26.4% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 57 | 450 | $50,850 | $13,314 | 26.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 88 | 152 | $31,920 | $11,410 | 35.7% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 17 | 140 | $28,980 | $10,604 | 36.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 228 | 975 | $14,625 | $8,151 | 55.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 37 | 37 | $21,053 | $7,334 | 34.8% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 56 | 458 | $36,182 | $7,228 | 20.0% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 181 | 701 | $40,658 | $7,211 | 17.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 231 | 944 | $41,536 | $7,157 | 17.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 125 | 480 | $35,925 | $6,377 | 17.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 31 | 92 | $22,448 | $6,006 | 26.8% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 27 | 142 | $15,762 | $4,065 | 25.8% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 14 | 111 | $21,867 | $3,810 | 17.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 25 | 25 | $11,525 | $3,262 | 28.3% |
| J1453 | Injection, fosaprepitant, 1 mg | Office | 2023 | 28 | 23,250 | $139,500 | $2,951 | 2.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 22 | 27 | $9,369 | $2,914 | 31.1% |
About Dr. Gigi Chen, M.D
Dr. Gigi Chen, M.D is a Hematology & Oncology healthcare provider based in Pleasant Hill, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/14/2005. The National Provider Identifier (NPI) number assigned to this provider is 1821073636.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gigi Chen, M.D has received a total of $132,511 in payments from pharmaceutical and medical device companies, with $4,528 received in 2024. These payments were reported across 650 transactions from 75 companies. The most common payment nature is "Consulting Fee" ($57,692).
As a Medicare-enrolled provider, Chen has provided services to 12,715 Medicare beneficiaries, totaling 445,754 services with total Medicare billing of $7.7M. Data is available for 4 years (2020–2023), covering 218 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Pleasant Hill, CA
- Active Since 12/14/2005
- Last Updated 08/02/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1821073636
Products in Payments
- ZEJULA (Drug) $54,332
- Stivarga (Drug) $10,506
- Yescarta (Drug) $5,216
- Venclexta (Biological) $5,011
- IMFINZI (Biological) $4,816
- CALQUENCE (Drug) $4,545
- TAGRISSO (Drug) $4,334
- LYNPARZA (Drug) $3,756
- Cabometyx (Drug) $2,863
- XPOVIO (Drug) $2,250
- VENCLEXTA (Drug) $2,250
- ABECMA (Biological) $1,976
- ADCETRIS (Biological) $1,695
- Vitrakvi (Drug) $1,692
- Nerlynx (Drug) $1,194
- Tavalisse (Drug) $1,020
- ONUREG (Drug) $885.00
- Trodelvy (Drug) $826.82
- INREBIC (Drug) $690.00
- IMBRUVICA (Drug) $446.53
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Pleasant Hill
Dr. Shoba Kankipati, M.d, M.D
Hematology & Oncology — Payments: $71,127
Hematology & Oncology $71,127
Dr. Leann Blankenship, M.d, M.D
Hematology & Oncology — Payments: $18,600
Hematology & Oncology $18,600
Donna Saba, Fnp, FNP
Hematology & Oncology — Payments: $16,904
Hematology & Oncology $16,904
Yelena Krupitskaya, M.d, M.D
Hematology & Oncology — Payments: $9,191
Hematology & Oncology $9,191
Robert Robles, M.d, M.D
Hematology & Oncology — Payments: $8,627
Hematology & Oncology $8,627
Tiffany Svahn, M.d, M.D
Hematology & Oncology — Payments: $5,476
Hematology & Oncology $5,476